BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Boguniewicz M, Alexis AF, Beck LA, Block J, Eichenfield LF, Fonacier L, Guttman-Yassky E, Paller AS, Pariser D, Silverberg JI, Lebwohl M. Expert Perspectives on Management of Moderate-to-Severe Atopic Dermatitis: A Multidisciplinary Consensus Addressing Current and Emerging Therapies. J Allergy Clin Immunol Pract 2017;5:1519-31. [PMID: 28970084 DOI: 10.1016/j.jaip.2017.08.005] [Cited by in Crossref: 63] [Cited by in F6Publishing: 53] [Article Influence: 12.6] [Reference Citation Analysis]
Number Citing Articles
1 Andersen Y, Egeberg A, Skov L, Thyssen J. Demographics, healthcare utilization and drug use in children and adults with atopic dermatitis in Denmark: a population‐based cross‐sectional study. J Eur Acad Dermatol Venereol 2019;33:1133-42. [DOI: 10.1111/jdv.15424] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
2 Fourzali K, Golpanian RS, Yosipovitch G. Dupilumab use in atopic dermatitis and beyond in skin diseases. Immunotherapy 2020;12:1221-35. [PMID: 32892674 DOI: 10.2217/imt-2020-0175] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
3 Beck LA, Thaçi D, Deleuran M, Blauvelt A, Bissonnette R, de Bruin-Weller M, Hide M, Sher L, Hussain I, Chen Z, Khokhar FA, Beazley B, Ruddy M, Patel N, Graham NMH, Ardeleanu M, Shumel B. Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis. Am J Clin Dermatol 2020;21:567-77. [PMID: 32557382 DOI: 10.1007/s40257-020-00527-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 14.0] [Reference Citation Analysis]
4 Gil TY, Hong CH, An HJ. Anti-Inflammatory Effects of Ellagic Acid on Keratinocytes via MAPK and STAT Pathways. Int J Mol Sci 2021;22:1277. [PMID: 33525403 DOI: 10.3390/ijms22031277] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Guttman-Yassky E, Brunner PM, Neumann AU, Khattri S, Pavel AB, Malik K, Singer GK, Baum D, Gilleaudeau P, Sullivan-Whalen M, Rose S, Jim On S, Li X, Fuentes-Duculan J, Estrada Y, Garcet S, Traidl-Hoffmann C, Krueger JG, Lebwohl MG. Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial. J Am Acad Dermatol 2018;78:872-881.e6. [PMID: 29353025 DOI: 10.1016/j.jaad.2018.01.016] [Cited by in Crossref: 142] [Cited by in F6Publishing: 125] [Article Influence: 35.5] [Reference Citation Analysis]
6 Mancuso JB, Lee SS, Paller AS, Ohya Y, Eichenfield LF. Management of Severe Atopic Dermatitis in Pediatric Patients. J Allergy Clin Immunol Pract 2021;9:1462-71. [PMID: 33838839 DOI: 10.1016/j.jaip.2021.02.017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Segawa R, Shiraki M, Sudo S, Shigeeda K, Saito T, Mizuno N, Moriya T, Yonezawa T, Woo JT, Hiratsuka M, Hirasawa N. A chalcone derivative suppresses the induction of TSLP in mice and human keratinocytes and attenuates OVA-induced antibody production in mice. Eur J Pharmacol 2019;851:52-62. [PMID: 30753864 DOI: 10.1016/j.ejphar.2019.02.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
8 Nezamololama N, Crowley EL, Gooderham MJ, Papp K. Abrocitinib: a potential treatment for moderate-to-severe atopic dermatitis. Expert Opin Investig Drugs 2020;29:911-7. [PMID: 32741227 DOI: 10.1080/13543784.2020.1804854] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Arakawa H, Shimojo N, Katoh N, Hiraba K, Kawada Y, Yamanaka K, Igawa K, Murota H, Okafuji I, Fukuie T, Nakahara T, Noguchi T, Kanakubo A, Katayama I. Consensus statements on pediatric atopic dermatitis from dermatology and pediatrics practitioners in Japan: Goals of treatment and topical therapy. Allergology International 2020;69:84-90. [DOI: 10.1016/j.alit.2019.08.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Boguniewicz M. Biologics for Atopic Dermatitis. Immunol Allergy Clin North Am 2020;40:593-607. [PMID: 33012322 DOI: 10.1016/j.iac.2020.06.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
11 Fenske C, Boytsov N, Guo J, Dawson Z. Prescription Market Share and Treatment Patterns in Atopic Dermatitis: A Retrospective Observational Study Using US Insurance Claims. Adv Ther 2022. [PMID: 35287230 DOI: 10.1007/s12325-022-02071-y] [Reference Citation Analysis]
12 Rieckmann P, Centonze D, Giovannoni G, Hua LH, Oreja-Guevara C, Selchen D, Sørensen PS, Vermersch P, Wiendl H, Salloukh H, Yamout B. Expert opinion on COVID-19 vaccination and the use of cladribine tablets in clinical practice. Ther Adv Neurol Disord 2021;14:17562864211058298. [PMID: 34899987 DOI: 10.1177/17562864211058298] [Reference Citation Analysis]
13 Gooderham MJ, Forman SB, Bissonnette R, Beebe JS, Zhang W, Banfield C, Zhu L, Papacharalambous J, Vincent MS, Peeva E. Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis: A Phase 2 Randomized Clinical Trial. JAMA Dermatol 2019;155:1371-9. [PMID: 31577341 DOI: 10.1001/jamadermatol.2019.2855] [Cited by in Crossref: 63] [Cited by in F6Publishing: 57] [Article Influence: 31.5] [Reference Citation Analysis]
14 Griffiths C, de Bruin-Weller M, Deleuran M, Fargnoli MC, Staumont-Sallé D, Hong CH, Sánchez-Carazo J, Foley P, Seo SJ, Msihid J, Chen Z, Cyr SL, Rossi AB. Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis and Prior Use of Systemic Non-Steroidal Immunosuppressants: Analysis of Four Phase 3 Trials. Dermatol Ther (Heidelb) 2021;11:1357-72. [PMID: 34142350 DOI: 10.1007/s13555-021-00558-0] [Reference Citation Analysis]
15 Chu CY. Treatments for Childhood Atopic Dermatitis: an Update on Emerging Therapies. Clin Rev Allergy Immunol 2021;61:114-27. [PMID: 32607924 DOI: 10.1007/s12016-020-08799-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
16 Beck LA, Thaçi D, Deleuran M, de Bruin-Weller M, Chen Z, Khokhar FA, Zhang M, Ozturk ZE, Shumel B. Laboratory safety of dupilumab for up to 3 years in adults with moderate-to-severe atopic dermatitis: results from an open-label extension study. J Dermatolog Treat 2021;:1-9. [PMID: 33557637 DOI: 10.1080/09546634.2020.1871463] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
17 Ariëns LFM, Bakker DS, van der Schaft J, Garritsen FM, Thijs JL, de Bruin-Weller MS. Dupilumab in atopic dermatitis: rationale, latest evidence and place in therapy. Ther Adv Chronic Dis 2018;9:159-70. [PMID: 30181845 DOI: 10.1177/2040622318773686] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
18 Lorz LR, Kim MY, Cho JY. Medicinal potential of Panax ginseng and its ginsenosides in atopic dermatitis treatment. J Ginseng Res 2020;44:8-13. [PMID: 32095092 DOI: 10.1016/j.jgr.2018.12.012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
19 Deleuran M, Thaçi D, Beck LA, de Bruin-Weller M, Blauvelt A, Forman S, Bissonnette R, Reich K, Soong W, Hussain I, Foley P, Hide M, Bouaziz JD, Gelfand JM, Sher L, Schuttelaar MLA, Wang C, Chen Z, Akinlade B, Gadkari A, Eckert L, Davis JD, Rajadhyaksha M, Staudinger H, Graham NMH, Pirozzi G, Ardeleanu M. Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study. J Am Acad Dermatol 2020;82:377-88. [PMID: 31374300 DOI: 10.1016/j.jaad.2019.07.074] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 16.0] [Reference Citation Analysis]
20 Lee JH, Lee SH, Ban GY, Ye YM, Nahm DH, Park HS, Shin YS. Factors Associated with Adherence to Allergen Specific Subcutaneous Immunotherapy. Yonsei Med J 2019;60:570-7. [PMID: 31124341 DOI: 10.3349/ymj.2019.60.6.570] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
21 Narla S, Silverberg JI, Simpson EL. Management of inadequate response and adverse effects to dupilumab in atopic dermatitis. J Am Acad Dermatol 2021:S0190-9622(21)01119-1. [PMID: 34126094 DOI: 10.1016/j.jaad.2021.06.017] [Reference Citation Analysis]
22 Brar KK, Nicol NH, Boguniewicz M. Strategies for Successful Management of Severe Atopic Dermatitis. The Journal of Allergy and Clinical Immunology: In Practice 2019;7:1-16. [DOI: 10.1016/j.jaip.2018.10.021] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
23 McKenzie PL, Rangu S, Treat JR, Castelo-Soccio L. Experience using dupilumab for pediatric atopic dermatitis at a tertiary care c enter: Inadequate response and adverse events. Pediatr Dermatol 2021;38:1178-84. [PMID: 34515353 DOI: 10.1111/pde.14799] [Reference Citation Analysis]
24 Diaz A, Guttman-Yassky E. Topical agents for the treatment of atopic dermatitis. Expert Rev Clin Immunol 2019;15:369-82. [PMID: 30587053 DOI: 10.1080/1744666X.2019.1564038] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 2.7] [Reference Citation Analysis]
25 El Hachem M, Di Mauro G, Rotunno R, Giancristoforo S, De Ranieri C, Carlevaris CM, Verga MC, Dello Iacono I. Pruritus in pediatric patients with atopic dermatitis: a multidisciplinary approach - summary document from an Italian expert group. Ital J Pediatr 2020;46:11. [PMID: 32000823 DOI: 10.1186/s13052-020-0777-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
26 Frampton JE, Blair HA. Dupilumab: A Review in Moderate-to-Severe Atopic Dermatitis. Am J Clin Dermatol 2018;19:617-24. [PMID: 30027349 DOI: 10.1007/s40257-018-0370-9] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 6.3] [Reference Citation Analysis]
27 Amat F, Soria A, Tallon P, Bourgoin-Heck M, Lambert N, Deschildre A, Just J. New insights into the phenotypes of atopic dermatitis linked with allergies and asthma in children: An overview. Clin Exp Allergy 2018;48:919-34. [PMID: 29676818 DOI: 10.1111/cea.13156] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
28 Kirchhof MG, Landells I, Lynde CW, Gooderham MJ, Hong CH. Approach to the Assessment and Management of Adult Patients With Atopic Dermatitis: A Consensus Document. Section I: Pathophysiology of Atopic Dermatitis and Implications for Systemic Therapy. J Cutan Med Surg 2018;22:6S-9S. [PMID: 30439299 DOI: 10.1177/1203475418803626] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
29 Sicras-Mainar A, Navarro-Artieda R, Armario-Hita JC. Severe Atopic Dermatitis In Spain: A Real-Life Observational Study. Ther Clin Risk Manag 2019;15:1393-401. [PMID: 31819466 DOI: 10.2147/TCRM.S226456] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
30 Silverberg JI, Toth D, Bieber T, Alexis AF, Elewski BE, Pink AE, Hijnen D, Jensen TN, Bang B, Olsen CK, Kurbasic A, Weidinger S; ECZTRA 3 study investigators. Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial. Br J Dermatol 2021;184:450-63. [PMID: 33000503 DOI: 10.1111/bjd.19573] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 29.0] [Reference Citation Analysis]
31 Kemény L, Varga E, Novak Z. Advances in phototherapy for psoriasis and atopic dermatitis. Expert Rev Clin Immunol 2019;15:1205-14. [PMID: 31575297 DOI: 10.1080/1744666X.2020.1672537] [Cited by in Crossref: 17] [Cited by in F6Publishing: 4] [Article Influence: 5.7] [Reference Citation Analysis]
32 Sørensen PS, Centonze D, Giovannoni G, Montalban X, Selchen D, Vermersch P, Wiendl H, Yamout B, Salloukh H, Rieckmann P. Expert opinion on the use of cladribine tablets in clinical practice. Ther Adv Neurol Disord 2020;13:1756286420935019. [PMID: 32636933 DOI: 10.1177/1756286420935019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
33 Sanchez J, Cherrez-Ojeda I, Galvan C, Garcia E, Hernández-Mantilla N, Londoño Garcia A, McElwee E, Rico Restrepo M, Rivas E, Hidalgo B. The Unmet Needs in Atopic Dermatitis Control in Latin America: A Multidisciplinary Expert Perspective. Dermatol Ther (Heidelb) 2021;11:1521-40. [PMID: 34449071 DOI: 10.1007/s13555-021-00595-9] [Reference Citation Analysis]
34 Radi G, Simonetti O, Rizzetto G, Diotallevi F, Molinelli E, Offidani A. Baricitinib: The First Jak Inhibitor Approved in Europe for the Treatment of Moderate to Severe Atopic Dermatitis in Adult Patients. Healthcare (Basel) 2021;9:1575. [PMID: 34828623 DOI: 10.3390/healthcare9111575] [Reference Citation Analysis]
35 Claeys N, Teeling MT, Legrand P, Poppe M, Verschueren P, De Prins L, Cools L, Cypers L, Fokkens WJ, Hopkins C, Hellings PW. Patients Unmet Needs in Chronic Rhinosinusitis With Nasal Polyps Care: A Patient Advisory Board Statement of EUFOREA. Front Allergy 2021;2:761388. [DOI: 10.3389/falgy.2021.761388] [Reference Citation Analysis]
36 Sawangjit R, Dilokthornsakul P, Lloyd-lavery A, Chua S, Lai NM, Dellavalle R, Chaiyakunapruk N; Cochrane Skin Group. Systemic treatments for eczema: a network meta-analysis. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd013206] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
37 Kim JE, Shin MK, Park GH, Lee UH, Lee JH, Han TY, Koh HC, Jang YH, Kim HO, Na CH, Lew BL, Ahn JY, Park CO, Seo YJ, Lee YW, Sohn SW, Park YL. 2019 Consensus Korean Diagnostic Guidelines to Define Severity Classification and Treatment Refractoriness for Atopic Dermatitis: Objective and Subjective Assessment of Severity. Ann Dermatol 2019;31:654-61. [PMID: 33911665 DOI: 10.5021/ad.2019.31.6.654] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
38 Mendes JT, Balogh EA, Strowd LC, Feldman SR. An evaluation of baricitinib as a therapeutic option for adult patients with moderate to severe atopic dermatitis. Expert Opin Pharmacother 2020;21:1027-33. [PMID: 32208940 DOI: 10.1080/14656566.2020.1739268] [Reference Citation Analysis]
39 Hudson RD, Ameen M, George SM, Harwood CA, Weller RB, Lear JT, Rout R, Surendranathan T, Petrovic M, Bewley AP. A Real-World Data Study on the Healthcare Resource Use for Uncontrolled Moderate-to-Severe Atopic Dermatitis in Secondary Care in the United Kingdom Prior to the Introduction of Biologic Treatment. CEOR 2022;Volume 14:167-77. [DOI: 10.2147/ceor.s333847] [Reference Citation Analysis]
40 Alyoussef A. Blocking TGF-β type 1 receptor partially reversed skin tissue damage in experimentally induced atopic dermatitis in mice. Cytokine 2018;106:45-53. [PMID: 29549723 DOI: 10.1016/j.cyto.2018.02.025] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
41 Chovatiya R, Silverberg JI. DESCRIBE-AD: A novel classification framework for atopic dermatitis. J Am Acad Dermatol 2021:S0190-9622(21)02795-X. [PMID: 34774658 DOI: 10.1016/j.jaad.2021.10.058] [Reference Citation Analysis]
42 Beck LA, Deleuran M, Bissonnette R, de Bruin-Weller M, Galus R, Nakahara T, Seo SJ, Khokhar FA, Vakil J, Xiao J, Marco AR, Levit NA, O'Malley JT, Shabbir A. Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis. Am J Clin Dermatol 2022. [PMID: 35503163 DOI: 10.1007/s40257-022-00685-0] [Reference Citation Analysis]
43 Petrova E, Hovnanian A. Advances in understanding of Netherton syndrome and therapeutic implications. Expert Opinion on Orphan Drugs 2020;8:455-87. [DOI: 10.1080/21678707.2020.1857724] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Freitas E, Guttman-Yassky E, Torres T. Tralokinumab for the Treatment of Atopic Dermatitis. Am J Clin Dermatol 2021;22:625-38. [PMID: 34155602 DOI: 10.1007/s40257-021-00613-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
45 Yun M, Park K, Yoon K, Choi H; Department of Beauty Science, Kwangju Women's University, 40 Gwangju-Yeodaegil (Sanjeong-dong), Gwangju 62396, South Korea, Department of Bio-Pharmacy, Daejeon Health Insitute of Technology, Daejeon 34504, South Korea, Department of Clinical Pathology, Daejeon Health Institute of Technology, Daejeon 34504, South Korea, Department of Beauty Art, 142 Bansong Beltway (Bansong-dong), Busan 48015, Youngsan University, South Korea. Nandina domestica Thunb ameliorate atopic dermatitis in NC/Nga mice treated with 1-chloro-2,4-dinitrobenzene (DNCB)]]>. AIMS Bioengineering 2021;8:154-64. [DOI: 10.3934/bioeng.2021014] [Reference Citation Analysis]
46 Janmohamed SR, Grosber M, Eichenfield LF, Ring J, Gutermuth J. Medical algorithm: Diagnosis of atopic dermatitis in early childhood (part I). Allergy 2021;76:403-6. [PMID: 33089496 DOI: 10.1111/all.14638] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
47 Shibata S, Kuwahara A, Sakaki-Yumoto M, Kawaguchi M, Ishii T, Honma Y. Effects of the dipeptide L-glutamic acid-L-tryptophan on dermatitis in mice and human keratinocytes. Heliyon 2022;8:e08729. [PMID: 35036609 DOI: 10.1016/j.heliyon.2022.e08729] [Reference Citation Analysis]
48 Eichenfield LF, Bieber T, Beck LA, Simpson EL, Thaçi D, de Bruin-Weller M, Deleuran M, Silverberg JI, Ferrandiz C, Fölster-Holst R, Chen Z, Graham NMH, Pirozzi G, Akinlade B, Yancopoulos GD, Ardeleanu M. Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis. Am J Clin Dermatol 2019;20:443-56. [PMID: 31066001 DOI: 10.1007/s40257-019-00445-7] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 15.3] [Reference Citation Analysis]
49 Rambhia PH, Levitt JO. Recalcitrant prurigo nodularis treated successfully with dupilumab. JAAD Case Rep 2019;5:471-3. [PMID: 31192991 DOI: 10.1016/j.jdcr.2019.03.016] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 6.7] [Reference Citation Analysis]
50 Smith S, Baker C, Gebauer K, Rubel D, Frankum B, Soyer HP, Weightman W, Sladden M, Rawlin M, Headley AP, Somerville C, Beuth J, Logan N, Mewton E, Foley P. Atopic dermatitis in adults: An Australian management consensus. Australas J Dermatol 2020;61:23-32. [PMID: 31372984 DOI: 10.1111/ajd.13124] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
51 Lee Y, Kim ME, Nahm DH. Real Clinical Practice Data of Monthly Dupilumab Therapy in Adult Patients With Moderate-to-Severe Atopic Dermatitis: Clinical Efficacy and Predictive Markers for a Favorable Clinical Response. Allergy Asthma Immunol Res 2021;13:733-45. [PMID: 34486258 DOI: 10.4168/aair.2021.13.5.733] [Reference Citation Analysis]
52 Gooderham MJ, Bissonnette R, Grewal P, Lansang P, Papp KA, Hong CH. Approach to the Assessment and Management of Adult Patients With Atopic Dermatitis: A Consensus Document. Section II: Tools for Assessing the Severity of Atopic Dermatitis. J Cutan Med Surg 2018;22:10S-6S. [PMID: 30439297 DOI: 10.1177/1203475418803628] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
53 Zhao Y, Zhang L, Ding Y, Tao X, Ji C, Dong X, Lu J, Wu L, Wang R, Lu Q, Goh AH, Liu R, Zhang Z, Zhang J. Efficacy and Safety of SHR0302, a Highly Selective Janus Kinase 1 Inhibitor, in Patients with Moderate to Severe Atopic Dermatitis: A Phase II Randomized Clinical Trial. Am J Clin Dermatol 2021. [PMID: 34374027 DOI: 10.1007/s40257-021-00627-2] [Reference Citation Analysis]
54 Alyoussef A. Attenuation of experimentally induced atopic dermatitis in mice by sulforaphane: effect on inflammation and apoptosis. Toxicol Mech Methods 2021;:1-9. [PMID: 34651546 DOI: 10.1080/15376516.2021.1994076] [Reference Citation Analysis]
55 Chan TC, Wu NL, Wong LS, Cho YT, Yang CY, Yu Y, Lai PJ, Chang YT, Shih IH, Lee CH, Chu CY. Taiwanese Dermatological Association consensus for the management of atopic dermatitis: A 2020 update. J Formos Med Assoc 2021;120:429-42. [PMID: 32564976 DOI: 10.1016/j.jfma.2020.06.008] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
56 van Os-Medendorp H, Deprez E, Maes N, Ryan S, Jackson K, Winders T, De Raeve L, De Cuyper C, Ersser S. The role of the nurse in the care and management of patients with atopic dermatitis. BMC Nurs 2020;19:102. [PMID: 33292229 DOI: 10.1186/s12912-020-00494-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
57 Huang C, Tang J. Sublingual immunotherapy with Dermatophagoides farinae drops for pediatric atopic dermatitis. Int J Dermatol 2021. [PMID: 34792188 DOI: 10.1111/ijd.15977] [Reference Citation Analysis]
58 Schatz M, Sicherer SH, Zeiger RS. The Journal of Allergy and Clinical Immunology: In Practice 2017 Year in Review. J Allergy Clin Immunol Pract 2018;6:328-52. [PMID: 29397373 DOI: 10.1016/j.jaip.2017.12.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
59 Sawangjit R, Dilokthornsakul P, Lloyd-Lavery A, Lai NM, Dellavalle R, Chaiyakunapruk N. Systemic treatments for eczema: a network meta-analysis. Cochrane Database Syst Rev 2020;9:CD013206. [PMID: 32927498 DOI: 10.1002/14651858.CD013206.pub2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
60 Guttman-Yassky E, Pavel AB, Zhou L, Estrada YD, Zhang N, Xu H, Peng X, Wen HC, Govas P, Gudi G, Ca V, Fang H, Salhi Y, Back J, Reddy V, Bissonnette R, Maari C, Grossman F, Wolff G. GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis. J Allergy Clin Immunol 2019;144:482-493.e7. [PMID: 30738171 DOI: 10.1016/j.jaci.2018.11.053] [Cited by in Crossref: 59] [Cited by in F6Publishing: 51] [Article Influence: 19.7] [Reference Citation Analysis]
61 Armario‐hita J, Pereyra‐rodriguez J, Silvestre J, Ruiz‐villaverde R, Valero A, Izu‐belloso R, Jáuregui‐presa I, Curto‐barredo L, Figueras‐nart I, Herranz‐pinto P, Herraez‐herrera L, Ortiz‐de‐frutos F, Martinez‐pilar L, Sastre J, Serra‐baldrich E. Treatment of moderate‐to‐severe atopic dermatitis with dupilumab in real clinical practice: a multicentre, retrospective case series. Br J Dermatol 2019;181:1072-4. [DOI: 10.1111/bjd.18041] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
62 Davis CM, Apter AJ, Casillas A, Foggs MB, Louisias M, Morris EC, Nanda A, Nelson MR, Ogbogu PU, Walker-McGill CL, Wang J, Perry TT. Health disparities in allergic and immunologic conditions in racial and ethnic underserved populations: A Work Group Report of the AAAAI Committee on the Underserved. J Allergy Clin Immunol 2021;147:1579-93. [PMID: 33713767 DOI: 10.1016/j.jaci.2021.02.034] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
63 Rodrigues MA, Nogueira M, Torres T. Dupilumab for atopic dermatitis: evidence to date. G Ital Dermatol Venereol 2019;154:696-713. [PMID: 31210470 DOI: 10.23736/S0392-0488.19.06417-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
64 Silverberg JI, Guttman-Yassky E, Gadkari A, Kuznik A, Mallya UG, Mastey V, Zhang H, Chen Z, Chen C, Korotzer A, Sierka D, Fenton MC, Kaur M, Jalbert JJ. Real-world persistence with dupilumab among adults with atopic dermatitis. Ann Allergy Asthma Immunol 2021;126:40-5. [PMID: 32739313 DOI: 10.1016/j.anai.2020.07.026] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
65 Espinoza LC, Vera-García R, Silva-Abreu M, Domènech Ò, Badia J, Rodríguez-Lagunas MJ, Clares B, Calpena AC. Topical Pioglitazone Nanoformulation for the Treatment of Atopic Dermatitis: Design, Characterization and Efficacy in Hairless Mouse Model. Pharmaceutics 2020;12:E255. [PMID: 32178278 DOI: 10.3390/pharmaceutics12030255] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
66 Di Paolo CT, Diamandis EP, Prassas I. The role of kallikreins in inflammatory skin disorders and their potential as therapeutic targets. Crit Rev Clin Lab Sci 2021;58:1-16. [PMID: 32568598 DOI: 10.1080/10408363.2020.1775171] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
67 Ruiz‐villaverde R, Dominguez‐cruz J, Armario‐hita JC, Martinez‐pilar L, Alcantara‐luna S, Pereyra‐rodriguez JJ. Fifty‐two week follow‐up safety and effectiveness results of dupilumab treatment of moderate‐to‐severe atopic dermatitis from a retrospective, multicentric series. Dermatologic Therapy 2019. [DOI: 10.1111/dth.12931] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
68 Basso L, Serhan N, Tauber M, Gaudenzio N. Peripheral neurons: Master regulators of skin and mucosal immune response. Eur J Immunol 2019;49:1984-97. [DOI: 10.1002/eji.201848027] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
69 Narla S, Silverberg JI. The suitability of treating atopic dermatitis with Janus kinase inhibitors. Expert Rev Clin Immunol 2022. [PMID: 35377276 DOI: 10.1080/1744666X.2022.2060822] [Reference Citation Analysis]
70 Aldredge LM. Atopic Dermatitis With a Focus on Moderate to Severe Disease. The Journal for Nurse Practitioners 2020;16:726-31. [DOI: 10.1016/j.nurpra.2020.08.026] [Reference Citation Analysis]
71 Fölster-Holst R, Torrelo A, Das K, Murrell DF, Patil A, Rahmat Pour Rokni G, Grabbe S, Staubach P, Sohn A, Goldust M. Biological medication in atopic dermatitis. Expert Opin Biol Ther 2022;:1-7. [PMID: 34991429 DOI: 10.1080/14712598.2022.2026920] [Reference Citation Analysis]
72 Dhadwal G, Albrecht L, Gniadecki R, Poulin Y, Yeung J, Hong C, Gooderham MJ. Approach to the Assessment and Management of Adult Patients With Atopic Dermatitis: A Consensus Document. Section IV: Treatment Options for the Management of Atopic Dermatitis. J Cutan Med Surg 2018;22:21S-9S. [DOI: 10.1177/1203475418805721] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]